1. Home
  2. BYFC vs CGTX Comparison

BYFC vs CGTX Comparison

Compare BYFC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadway Financial Corporation

BYFC

Broadway Financial Corporation

N/A

Current Price

$11.66

Market Cap

90.3M

Sector

Finance

ML Signal

N/A

CGTX

Cognition Therapeutics Inc.

BUY

Current Price

$0.72

Market Cap

79.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
BYFC
CGTX
Founded
1946
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.3M
79.6M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
BYFC
CGTX
Price
$11.66
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
1.7K
★ 470.4K
Earning Date
07-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 62.79
EPS
★ 0.07
N/A
Revenue
★ $184,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$162.43
★ N/A
Revenue Growth
★ 18.71
N/A
52 Week Low
$5.51
$0.55
52 Week High
$12.35
$1.93

Technical Indicators

Market Signals
Indicator
BYFC
CGTX
Relative Strength Index (RSI) 39.55 23.38
Support Level $9.29 $0.55
Resistance Level $12.27 $1.18
Average True Range (ATR) 0.14 0.06
MACD -0.06 -0.02
Stochastic Oscillator 0.00 7.18

Price Performance

Historical Comparison
BYFC
CGTX

About BYFC Broadway Financial Corporation

Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: